Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/4334
Title: | Long-term results of adjunctive use of mitomycin C in external dacryocystorhinostomy | Authors: | Yıldırım, Cem. Yaylalı, Volkan. Eşme, Arif. Özden, Serap. |
Keywords: | Dacryocystorhinostomy Mitomycin C Nasolacrimal duct obstruction Tearing mitomycin C adjuvant therapy adult article clinical article clinical trial controlled clinical trial controlled study dacryocystorhinostomy drug efficacy drug safety epistaxis eye infection gastrointestinal irritation human lacrimal duct occlusion lacrimation mucosal necrosis nose irritation postoperative complication randomized controlled trial scar statistical significance treatment outcome Adult Alkylating Agents Humans Intraoperative Care Lacrimal Duct Obstruction Middle Aged Mitomycin Nasolacrimal Duct Patient Satisfaction Time Factors Treatment Outcome |
Abstract: | Objective: To assess the long-term results of intraoperative mitomycin C (MMC) in external dacryocystorhinostomy (EXT-DCR). Methods: In this prospective randomized controlled study, 35 patients (40 eyes) with primary acquired nasolacrimal duct obstruction were assigned randomly into two groups. In the control group, a standard EXT-DCR procedure was performed. In the MMC group 0.2 mg/ml MMC was applied to the osteotomy site for 30 min. The results of EXT-DCR in both groups were evaluated by both asking patients about the tearing condition and examining the patency of irrigation at one-year follow up. Results: Eighteen (90%) of the 20 eyes in the MMC group remained totally symptom-free and one eye (5%) improved; while 12 (60%) of 20 eyes in the control group were reported to be symptom-free and five (25%) of the eyes to have an improvement in the tearing symptoms (P = 0.087). The success rate in the MMC group was 95% compared with 85% in the control group (P = 0.605). No surgical complications occurred. Conclusions: The satisfaction and success rates of the MMC group were higher than those of the control group and no deleterious effect was noted with MMC application, however the differences did not reach statistical significance. Intraoperative MMC application seems to be a safe adjuvant that could help in increasing the success rates of EXT-DCR surgery in primary acquired nasolacrimal duct obstruction, however further studies with larger series are needed to make definite statements. © Springer Science+Business Media, Inc. 2007. | URI: | https://hdl.handle.net/11499/4334 https://doi.org/10.1007/s10792-007-9057-6 |
ISSN: | 0165-5701 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
SCOPUSTM
Citations
39
checked on Nov 16, 2024
Page view(s)
56
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.